SYMEXITY Trademark

Trademark Overview

On Monday, January 27, 2020, a trademark application was filed for SYMEXITY with the United States Patent and Trademark Office. The USPTO has given the SYMEXITY trademark a serial number of 88774747. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 26, 2022. This trademark is owned by COHERUS BIOSCIENCES, INC.. The SYMEXITY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the treatment of cancer, autoimmune diseases, metabolic diseases, or ophthalmic diseases and conditions; Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, metabolic diseases, or ophthalmic diseases and conditions
symexity

General Information

Serial Number88774747
Word MarkSYMEXITY
Filing DateMonday, January 27, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 26, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 29, 2020

Trademark Statements

Goods and ServicesPharmaceuticals for the treatment of cancer, autoimmune diseases, metabolic diseases, or ophthalmic diseases and conditions; Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, metabolic diseases, or ophthalmic diseases and conditions

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 31, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCOHERUS BIOSCIENCES, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressREDWOOD CITY, CA 94065
Party NameCOHERUS BIOSCIENCES, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressREDWOOD CITY, CA 94065

Trademark Events

Event DateEvent Description
Tuesday, December 27, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 26, 2022ABANDONMENT - NO USE STATEMENT FILED
Saturday, May 21, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 19, 2022SOU EXTENSION 3 GRANTED
Thursday, May 19, 2022SOU EXTENSION 3 FILED
Thursday, May 19, 2022TEAS EXTENSION RECEIVED
Thursday, November 18, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 16, 2021SOU EXTENSION 2 GRANTED
Tuesday, November 16, 2021SOU EXTENSION 2 FILED
Tuesday, November 16, 2021TEAS EXTENSION RECEIVED
Saturday, May 8, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 6, 2021SOU EXTENSION 1 GRANTED
Thursday, May 6, 2021SOU EXTENSION 1 FILED
Thursday, May 6, 2021TEAS EXTENSION RECEIVED
Tuesday, November 24, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 29, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 29, 2020PUBLISHED FOR OPPOSITION
Wednesday, September 9, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 27, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 26, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 25, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 25, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 2, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 2, 2020NON-FINAL ACTION E-MAILED
Monday, March 2, 2020NON-FINAL ACTION WRITTEN
Thursday, February 27, 2020ASSIGNED TO EXAMINER
Friday, January 31, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, January 30, 2020NEW APPLICATION ENTERED IN TRAM

Related Keywords

symexity diseases ophthalmic conditions treatment metabolic autoimmune cancer preparations pharmaceutical pharmaceuticals